Wizemann, Theresa, Robinson, Sally, Giffin, Robert. "4 Diverse Funding Models." Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary. Washington, DC: The National Academies Press, 2008.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies - Workshop Summary
onded the need for reliable authentication methods for pharmaceuticals. She noted that some of the countries most affected by the problem are beginning to address counterfeiting and are placing greater emphasis on drug quality. Hale has observed that when poor people are very sick and fear they may die, they ask for injections instead of oral products because in their experience, oral products are of poor quality. This is why OneWorld Health developed an injectable intramuscular paromomycin for visceral leishmaniasis. Corr cited two approaches to the problems of counterfeiting and reimportation currently being used by pharmaceutical companies: manufacturing pills that are shipped to developing countries in a different color, which decreases the pills’ reimportation into the developed world, and radiofrequency identification tagging, which can now be done on a capsule or ampule.